Navigation Links
Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/14/2011

and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.  A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complem
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
3. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
4. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... Research and Markets( http://www.researchandmarkets.com/research/hmdflj/outlook_of_global ) has ... Biologic Drug Discovery Outsourcing Market" report to their ... market will likely grow in a CAGR of 23% ... by 2020. It has been widely recognized ... new but important type of medication. They provide not ...
(Date:7/7/2015)... June 30, 2015 ... addition of the "Deciphering Global Major Pharmaceutical ... to their offering. It has been ... been involved in a series of challenges in ... resulted in significant overcapacities in small molecule product ...
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
Breaking Medicine Technology:Outlook of Global Biologic Drug Discovery Outsourcing Market to 2020 2Outlook of Global Biologic Drug Discovery Outsourcing Market to 2020 3Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3
... PASADENA, Calif. March 2, 2011 Men who take non-steroidal ... months are 2.4 times more likely to have erectile dysfunction ... according to a Kaiser Permanente study published online in ... research showed a trend toward this same finding, this observational ...
... The U.S. Food and Drug Administration today took ... unapproved prescription oral cough, cold, and allergy products. The ... States. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... have not been evaluated by the FDA for safety, ...
Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3FDA Prompts Removal of Unapproved Drugs From Market 2FDA Prompts Removal of Unapproved Drugs From Market 3
(Date:7/7/2015)... ... 07, 2015 , ... SC&H Group, a leading audit, tax, and consulting firm, ... the community through company-wide volunteering efforts. , On an annual basis, in coordination with ... those in need throughout Baltimore and Washington D.C. , This year, SC&H ...
(Date:7/7/2015)... Hong Kong (PRWEB) , ... July 07, 2015 , ... At the end of June ... first steps to ‘go green’ . This initiative, spearheaded by the Renewals Manager, Danielle Cotton, ... Hong Kong office. , On this initiative Cotton explained, “We send anything between 300 ...
(Date:7/7/2015)... R.I. (PRWEB) , ... July 07, 2015 , ... Summer ... the proper precautions, however, so Amica Insurance is sharing some safety tips. , Jean ... sports and gardening: , Leisure activities/sports, , Start slowly. Going ...
(Date:7/7/2015)... ... July 07, 2015 , ... Healthpointe is proud to ... Alupay, an anesthesiologist and pain management specialist, will be evaluating and treating patients with ... conditions. , After receiving his Bachelor of Science in Biology from the University of ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2
... Sheets: USFM ), announces the launch of ... which will operate as a division of US Farms Inc. ... wholesales for $89.95 per case (12 bottles). US Farms Aloe Vera ... American Express or by calling customer service 877-90-FARMS. , , ...
... play a pivotal role in moving services into less expensive yet clinically ... and policy firm KNG Health Consulting. Other key findings from the study, ... 2007, include: , , , , ... and cancer screening services. , 70% ...
... ... it is the first home health agency in California to implement an ... to improve health care. This home health software service equips all ... the point of care, reduces costs, improves efficiency and enhances communication across ...
... , MINNEAPOLIS, June 16 Excell Home Care & ... hospice services in Oklahoma, announced it has entered into ... telehealth technology to patients with chronic illness. Cardiocom, ... manufacturer and clinical service provider of award-winning telehealth solutions. ...
... injectable nano-emulsion formulated with, AlphaRx,s proprietary drug ... behavioral models. Gaia BioPharma plans to, initiate ... acute and as yet, unmet neurological indication., ... Inc. (OTCBB: ALRX) and Gaia BioPharma Limited, a privately held, ...
... Governor Pat Quinn and Mayor Richard Daley Declare June 27, 2009 ... State of Illinois , , CHICAGO, June 16 ... Chicago Hispanic Health Coalition to present Chicago,s third-annual Vive ... The event promotes family physical activity for better health and ...
Cached Medicine News:Health News:US Farms, Inc. Launches Aloe Vera Juice Web Site for Hispanic Market 2Health News:US Farms, Inc. Launches Aloe Vera Juice Web Site for Hispanic Market 3Health News:Ambulatory Surgery Centers 'Pivotal' in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings 2Health News:Ambulatory Surgery Centers 'Pivotal' in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings 3Health News:Ambulatory Surgery Centers 'Pivotal' in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings 4Health News:Ambulatory Surgery Centers 'Pivotal' in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings 5Health News:New Online Home Health Service Launched in California to Expand Direct Patient Care Time While Lowering Costs 2Health News:New Online Home Health Service Launched in California to Expand Direct Patient Care Time While Lowering Costs 3Health News:Excell Home Care & Hospice, Inc. Selects Cardiocom Telehealth Technology 2Health News:AlphaRx and Gaia BioPharma Provide GAI-122 Development Update 2Health News:Chicago Hispanic Health Coalition Presents Third-Annual Vive tu Vida! Get Up! Get Moving!(TM) Event 2
... The modular Doro headrest system ... and non-invasive applications in head ... be adapted to all standard ... decisive advantages and improvements in ...
Bunnel hand drill with Jacobs chuck, chuck size 4 mm....
Children's hospital hand drill, hexagonal handle, twist drill diameter 4.2 mm....
Hudson Drill hand drill....
Medicine Products: